Press Releases

May 19, 2026

New

DNAnexus Scales AI-Driven Capabilities

17-Year Multiomics Pioneer Powers Next Era of Precision Health

May 07, 2026

DNAnexus Wins MedTech Breakthrough’s PharmaTech Innovation Award

Enterprise Leading Orchestration Platform Honored for AI-Enabled Infrastructure and Next-Gen Digital Health & Medical Technology

May 07, 2026

Longitude Prize on ALS Announces Stage 1 Discovery Award Winners

Meet the Discovery Awardees of the Longitude Prize on ALS, awarded £100,000 each, as well as access to the Prize datasets and a technical support package to drive their computational work. These 20 pioneering, global and multidisciplinary teams are using cutting-edge AI to unlock the complexity of ALS.

November 10, 2025

EpiCypher Launches CUTANA® Cloud, a Powerful Epigenomic Data Analysis Platform

EpiCypher’s new bioinformatics platform, powered by DNAnexus, accelerates data analysis for leading chromatin mapping technologies including CUT&RUN and CUT&Tag.

October 22, 2025

DNAnexus Honored with Frost & Sullivan’s 2025 Technology Innovation Leadership Award

DNAnexus earned recognition from Frost & Sullivan for its leadership in precision health informatics. The award highlights its groundbreaking platform for integrating complex clinical, multi-omics, and real-world data to deliver secure, actionable insights.

September 11, 2025

DNAnexus and Oracle Join Forces to Deliver Genomic Insights at the Point of Care

Collaboration to enable healthcare professionals to access and interpret genomic data alongside patient medical history within Oracle Health EHR.

August 27, 2025

DNAnexus Enhances Leadership to Fuel AI Innovation and Biopharma Expansion

Company appoints Pieter De Leenheer as Chief Technology Officer and Todd Oakland as Senior Vice President and General Manager of Biopharma Business Dx/Rx

August 14, 2025

DNAnexus & Boehringer Ingelheim Named 2025 Prix Galien USA Nominee in Best Digital Health Solution for Project PRISM/Project CRYPTx

This recognition highlights an emerging model for dynamic, cloud-based regulatory collaboration.

June 25, 2025

£7.5 million Longitude Prize on ALS launches

The Longitude Prize on ALS, a £7.5 million global challenge prize, has launched to incentivise and reward cutting edge AI-based approaches to transform drug discovery for the treatment of ALS (amyotrophic lateral sclerosis), the most common form of MND (motor neurone disease).

May 20, 2025

ARPA-H pioneers game-changing cancer care designed to adapt throughout treatment

Selected performer teams will use predictive models to match treatments with changing tumor biology and prevent disease progression.

May 01, 2025

Latin-American genetic data available securely to approved researchers worldwide

Genetic data from the largest blood-based prospective study of a Latin-American population are now available securely to academic researchers worldwide through the DNAnexus Trusted Research Environment (TRE).

March 24, 2025

DNAnexus Announces Collaboration with AlidaBio to Enhance RNA Modification and Expression Analysis

AlidaBio EpiPlex™ customers now have cloud access to the EpiScout™ analysis software on DNAnexus’ secure, scalable precision health data cloud platform

February 03, 2025

DNAnexus Expands Relationship with Veeva to Advance Global Regulatory Collaboration

Companies come together to connect sponsors, agencies, and standards development organizations on a regulatory collaboration cloud

December 18, 2024

DNAnexus Recognized by Frost & Sullivan for Ability to Integrate and Synchronize Diverse Clinical and Multi-omics Data

Frost & Sullivan researched the bioinformatics-based drug discovery and development industry, and based on its analysis results, today recognized DNAnexus, provider of the leading enterprise platform for precision health data, with the 2024 Global Enabling Technology Leadership Award in the "bioinformatics-based drug discovery and development industry" category.

December 09, 2024

DNAnexus and Panomics Join Forces to Deliver Comprehensive, Interactive Multi-omics Data Solutions for Biopharma Organizations

Researchers can conduct large-scale transcriptomics and proteomics data analyses on secure, cloud-based platform to accelerate biomarker discovery and drug repurposing applications.

View More →

News

May 29, 2026

New

Immunai, AstraZeneca Expand Partnership, Rancho Biosciences Releases Multi-omics Datasets, Dotmatics AI Co-Scientist

By bridging the gap between raw multimodal data and clinical discovery, DNAnexus enables health leaders to operationalize AI across critical workflows with full regulatory readiness.

May 26, 2026

Programming biology: next-gen AI firms raise billions to design better medicines

Faster drug discovery, optimized drug design, even programmable therapeutics: AI is impacting R&D. Data and development bottlenecks remain.

May 19, 2026

DNAnexus AI Products

DNAnexus has launched a number of software products and enhancements that are enabled by artificial intelligence.

May 01, 2026

How are companies distinguishing between “moonshot” automation and validated digital tools that can be deployed today?

Todd Oakland, Ph.D., Senior Vice President, General Manager, Biopharma RX/DX, DNAnexus, joins a roundtable of experts to discuss the pace of technological innovation and how to tell when a tool is production-ready.

March 31, 2026

AI-led selloff in contract research firms may be misjudging disruption risk

Shares of contract research organizations have tumbled on fears that advances in artificial intelligence could allow drugmakers to take clinical trial work in-house, but industry experts say the selloff overestimates how far the technology can replace the sector's core capabilities.

February 02, 2026

Accelerating the drug regulatory process through a federated cloud ecosystem

Cloud-based regulatory platforms are transitioning from pilots to practical solutions. Sustainable adoption now relies on global coordination, continued trust and a shift towards federated, interoperable models.

January 21, 2026

The Top Healthcare Technology CEOs of 2025

The Healthcare Technology Report named DNAnexus CEO Thomas Laur as one of the Top Healthcare Technology CEOs of 2025. He was recognized for his leadership of our advanced platform that speeds critical decisions, reduces administrative drag, and supports research and care delivery across hospitals, employers, payers, and patients.

January 21, 2026

theCUBE + NYSE Wired: MedTech Unplugged Interview with Thomas Laur

Thomas spoke with theCUBE’s John Furrier as part of the CUBE + NYSE Wired: MedTech Unplugged: The Future of AI in Healthcare & Life Sciences event. They discuss why “omics” is becoming a core data object in modern care and what it takes to make precision medicine operational across the healthcare continuum and why AI’s upside in healthcare depends on more organized, omics-enabled data.

January 20, 2026

How DNAnexus is enabling precision medicine from research to the point of care

DNAnexus is pushing precision medicine out of research silos to improve care delivery. As CEO Thomas Laur puts it, “The future isn’t moving data into one big bucket. It’s moving algorithms to federated data,” enabling distributed clinical decisions at scale.

January 08, 2026

The ADAPT learning cancer treatment system: ARPA-H’s initiative to revolutionize cancer therapy

ADAPT is a nationwide initiative to transform cancer care by detecting and responding to tumor evolution in real time. Integrating multimodal data, interpretable AI, and an evolutionary clinical trial platform, ADAPT predicts emerging resistance traits and guides treatment adjustments as tumors change.

September 12, 2025